The Principals from Merck Capital Ventures (MCV) are raising a second $100 million fund that focuses exclusively on technologies for process improvement in the biopharmaceutical industry (not on therapeutic agents). 

Since 2000, the team has delivered top quartile financial returns in managing the venture fund for Merck & Co., Inc.  The new fund, Pharma Capital Ventures (PCV), will be led by the same team, with the same scope and size as the first fund. 

The Principals have developed a proven approach to investing, which draws on industry experts to understand market needs and find effective solutions.  The approach has generated proprietary deal flow that is not visible to other venture capital firms. 

The team has established strategic collaborations with several leading biopharmaceutical firms to identify and evaluate technologies and to provide emerging companies high level access to the industry.  The new fund is well-positioned to immediately apply capital, with a significant number of vetted opportunities.